

Bladder Cancer Treatment Response Prediction: Comparison with Published Studies




Figure 5. Literature comparison demonstrating competitive advantage of our multi-modal fusion approach. Our method achieves 13.4% improvement over baseline (Zhang et al. 2017) and outperforms recent bladder cancer studies through comprehensive integration of four genomic modalities with advanced feature selection and ensemble fusion strategies.